<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762385</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0713</org_study_id>
    <nct_id>NCT00762385</nct_id>
  </id_info>
  <brief_title>Clinical Comparison of Two Silicone-Hydrogel Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foresight Regulatory Strategies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Visioncare Research Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical performance of two silicone-hydrogel
      contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lens Comfort</measure>
    <time_frame>1-week, 2- weeks</time_frame>
    <description>&gt;0 = comfortable, &lt;0 = uncomfortable; a weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort Symptoms</measure>
    <time_frame>1-week, 2-weeks</time_frame>
    <description>A weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes. &gt;0 = comfortable, &lt;0 = uncomfortable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Corneal Staining</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measured for 5 zones of the cornea (superior, nasal, central, inferior, temporal)on a 0 to 3 grade scale (NEI 0-3 scale). Grade 0 = Normal/ grade 1 = mild, superficial stippling/ grade 2 = moderate, punctate staining including superficial abrasion of the cornea/ grade 3 = severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>galyfilcon A/comfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>galyfilcon A first, comfilcon A second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comfilcon A/galyfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comfilcon A first, galyfilcon A second</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyfilcon A</intervention_name>
    <description>galyfilcon A</description>
    <arm_group_label>galyfilcon A/comfilcon A</arm_group_label>
    <arm_group_label>comfilcon A/galyfilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>comfilcon A</intervention_name>
    <description>comfilcon A</description>
    <arm_group_label>galyfilcon A/comfilcon A</arm_group_label>
    <arm_group_label>comfilcon A/galyfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be at least 18 and less than or equal to 39 years of age and have a
             need for vision correction in both eyes.

          -  The subject must require a lens power between -1.00 to -6.00D and have no more than
             1.00D of corneal cylinder.

          -  The subject, based on his/her knowledge, must be in good general health.

          -  The subject must be able and willing to adhere to the instructions set forth in this
             protocol and complete all specified evaluations.

          -  Subject must be a current adapted daily wearer of soft contact lenses with at least 6
             months of CL wear.

          -  Subject must agree to wear their contact lenses in both eyes on a daily wear schedule
             for at least 8 hours per day every day during the study.

          -  Subject must be willing and able to use only the care systems and lubricating drops
             provided for the study during the 4 week period.

          -  The subject must read, indicate understanding of and sign the Informed Consent Form.

        Exclusion Criteria:

          -  The subject is a rigid gas permeable (RGP) or daily disposable lens wearer.

          -  The presence of clinically significant (grade 3 or 4) anterior segment abnormalities;
             inflammations such as iritis; or any infection of the eye, lids or associated
             structures.

          -  The presence of ocular or systemic disease or need for medication which might
             interfere with contact lens wear or which would cause the lenses to be removed more
             than twice a day. (i.e., Sjogren's syndrome, type II diabetes, etc.)

          -  Slit lamp findings that would contraindicate contact lens wear such as:

               -  pathological dry eye or associated findings

               -  pterygium or corneal scars within the visual axis

               -  neovascularization equal to or greater than 1mm in from the limbus

               -  history of giant papillary conjunctivitis (GPC) worse than grade 2

               -  anterior uveitis or iritis (past or present)

               -  seborrhoeic eczema

               -  seborrhoeic conjunctivitis

          -  A history of recurrent erosions, corneal infiltrates, corneal ulcer or fungal
             infections.

          -  A known history of corneal hypoesthesia (reduced corneal sensitivity).

          -  Contact lens snellen visual acuities (VA) worse than 20/30.

          -  Aphakia, keratoconus or a highly irregular cornea.

          -  Current pregnancy or lactation (to the best of the subject's knowledge)

          -  Any active participation in another clinical study at any time during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>December 5, 2008</results_first_submitted>
  <results_first_submitted_qc>January 22, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2010</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Galyfilcon A / Comfilcon A</title>
          <description>galyfilcon A contact lenses first period, comfilcon a contact lenses second period</description>
        </group>
        <group group_id="P2">
          <title>Comfilcon A / Galyfilcon A</title>
          <description>comfilcon A contact lenses first period, galyfilcon A contact lenses second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lens Issue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Completed Population</title>
          <description>Includes subjects randomized to galyfilcon A/comfilcon A and comfilcon A/galyfilcon A and that completed the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lens Comfort</title>
        <description>&gt;0 = comfortable, &lt;0 = uncomfortable; a weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes.</description>
        <time_frame>1-week, 2- weeks</time_frame>
        <population>Only participants who completed the study per protocol (n=78)</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A</title>
            <description>galyfilcon A administered in either the first intervention period or the second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>comfilcon A administered in either the first intervention period or second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Comfort</title>
          <description>&gt;0 = comfortable, &lt;0 = uncomfortable; a weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes.</description>
          <population>Only participants who completed the study per protocol (n=78)</population>
          <units>combined score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1452" spread="0.1097"/>
                    <measurement group_id="O2" value="0.1135" spread="0.1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results is overall lens effect with time as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1247</dispersion_value>
            <ci_percent>98.3</ci_percent>
            <ci_lower_limit>-0.2346</ci_lower_limit>
            <ci_upper_limit>0.03164</ci_upper_limit>
            <estimate_desc>Mean difference is galyfilcon A minus comfilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Corneal Staining</title>
        <description>Measured for 5 zones of the cornea (superior, nasal, central, inferior, temporal)on a 0 to 3 grade scale (NEI 0-3 scale). Grade 0 = Normal/ grade 1 = mild, superficial stippling/ grade 2 = moderate, punctate staining including superficial abrasion of the cornea/ grade 3 = severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
        <time_frame>2 weeks</time_frame>
        <population>Only the participants who completed the study per protocol (n=78)</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A</title>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Corneal Staining</title>
          <description>Measured for 5 zones of the cornea (superior, nasal, central, inferior, temporal)on a 0 to 3 grade scale (NEI 0-3 scale). Grade 0 = Normal/ grade 1 = mild, superficial stippling/ grade 2 = moderate, punctate staining including superficial abrasion of the cornea/ grade 3 = severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.</description>
          <population>Only the participants who completed the study per protocol (n=78)</population>
          <units>combined score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07582" spread="0.02192"/>
                    <measurement group_id="O2" value="0.07026" spread="0.02192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results is overall lens effect with time as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.005560</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02287</dispersion_value>
            <ci_percent>98.3</ci_percent>
            <ci_lower_limit>-0.04297</ci_lower_limit>
            <ci_upper_limit>0.005560</ci_upper_limit>
            <estimate_desc>Mean difference is galyfilcon A minus comfilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comfort Symptoms</title>
        <description>A weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes. &gt;0 = comfortable, &lt;0 = uncomfortable</description>
        <time_frame>1-week, 2-weeks</time_frame>
        <population>Only participants who completed the study per protocol (n=78)</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A</title>
            <description>galyfilcon A administered in either the first intervention period or the second intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>comfilcon A administered in either the first intervention period or the second intervention period.</description>
          </group>
        </group_list>
        <measure>
          <title>Comfort Symptoms</title>
          <description>A weighted combined score calculated from individual comfort-related questions was used to derive comfort outcomes. &gt;0 = comfortable, &lt;0 = uncomfortable</description>
          <population>Only participants who completed the study per protocol (n=78)</population>
          <units>score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2440" spread="0.1262"/>
                    <measurement group_id="O2" value="-0.02862" spread="0.1275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Results is overall lens effect with time as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2726</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1064</dispersion_value>
            <ci_percent>98.3</ci_percent>
            <ci_lower_limit>0.04553</ci_lower_limit>
            <ci_upper_limit>0.2726</ci_upper_limit>
            <estimate_desc>Mean difference is galyfilcon A minus comfilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Galyfilcon A / Comfilcon A</title>
          <description>galyfilcon A contact lenses first period, comfilcon a contact lenses second period</description>
        </group>
        <group group_id="E2">
          <title>Comfilcon A / Galyfilcon A</title>
          <description>comfilcon A contact lenses first period, galyfilcon A contact lenses second period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody, OD FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

